Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma

Fineline Cube Mar 18, 2024

BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...

Company Deals

Hansoh Pharmaceutical Secures Global Rights to Biotheus’ BsAb HS-20117/PM1080

Fineline Cube Mar 18, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has...

Company Policy / Regulatory

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Drug

Legend Biotech’s Carvykti Earns FDA Committee’s Unanimous Recommendation for Expanded Use

Fineline Cube Mar 18, 2024

GenScript Biotech Corporation (HKG: 1548), a Contract Research Organization (CRO) based in China, has announced...

Company Deals

Microenergy Medical Technology Secures Pre-Series A Funding to Advance Medical Devices

Fineline Cube Mar 18, 2024

Microenergy Medical Technology Co., Ltd, a Hangzhou-based manufacturer of active intervention medical devices, has reportedly...

Company Deals

Getein Biotech Partners with Dymind Biotechnology to Advance IVD Market Presence

Fineline Cube Mar 18, 2024

Getein Biotech Inc., (SHA: 603387), a company based in China with a focus on in...

Company Deals

CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development

Fineline Cube Mar 18, 2024

CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...

Company Drug

Simcere Pharmaceutical’s Suvemcitug Files for Approval in China for Recurrent Ovarian Cancer

Fineline Cube Mar 18, 2024

Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that an...

Company Drug

Bristol Myers Squibb’s Breyanzi Receives FDA Accelerated Approval for CLL/SLL Treatment

Fineline Cube Mar 18, 2024

The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s...

Company Drug

Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH

Fineline Cube Mar 18, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study

Fineline Cube Mar 18, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company

Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth

Fineline Cube Mar 18, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...

Company Drug

Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market

Fineline Cube Mar 18, 2024

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...

Company Drug

FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma

Fineline Cube Mar 18, 2024

An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...

Company Drug

Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR

Fineline Cube Mar 15, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...

Company Deals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline

Fineline Cube Mar 15, 2024

AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...

Company Drug

KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma

Fineline Cube Mar 15, 2024

Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...

Company Deals

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Fineline Cube Mar 15, 2024

Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...

Company Drug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

Fineline Cube Mar 15, 2024

Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...

Company Drug

Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults

Fineline Cube Mar 15, 2024

The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...

Posts pagination

1 … 376 377 378 … 653

Recent updates

  • China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.